Fisetin

TL;DR

Fisetin is the most potent standalone natural senolytic identified by the Mayo Clinic (Robbins/Niedernhofer/Kirkland labs), outperforming quercetin as monotherapy. It acts as a natural BH3 mimetic — binds Bcl-2/Bcl-xL hydrophobic grooves, displaces BAX/BAK → mitochondrial apoptosis in senescent cells. Also strongly neuroprotective (BBB-crossing, BDNF↑, tau aggregation prevention, ferroptosis inhibition). Critical caveats: potent CYP2C9 inhibitor — strictly contraindicated with warfarin; 2024 pilot showed 5/10 healthy non-frail adults had increased epigenetic aging — avoid prophylactically in healthy people. Active Phase II human trials (AFFIRM-LITE).

Why it matters for Vitals

Mayo Clinic-backed senolytic — the most evidence-validated natural senolytic in the longevity literature
Neuroprotective mechanisms (BDNF, tau, ferroptosis) map to cognitive/biometric readouts relevant to brain-age tracking
The CYP2C9 warfarin interaction is a hard clinical contraindication — any Vitals protocol involving fisetin must include a drug interaction check
2024 healthy-adult warning means fisetin should be targeted at high-senescent-cell-burden populations (frail, aged, metabolic disease), not used prophylactically
mTOR + autophagy mechanisms align with rapamycin and urolithin A stack logic

Key Facts


Status	OTC supplement; AFFIRM-LITE (NCT03675724) Phase II active
Class	Flavonoid (flavonol) / natural senolytic / senomorphic / Nrf2 activator
Core mechanism	Natural BH3 mimetic — binds Bcl-2/Bcl-xL → displaces BAX/BAK → mitochondrial apoptosis; also inhibits PI3K/Akt/mTOR, activates SIRT1/Nrf2/GPX4
Key advantage over D+Q	No dasatinib toxicity (PAH, cytopenias); wider therapeutic index; prophylactic use viable
Dosing	20 mg/kg × 2 days/month (senolytic burst) OR 500 mg/day continuous (neuroprotection)
Main risks	CYP2C9/warfarin contraindication; 5/10 healthy adults showed epigenetic acceleration (2024 pilot); low oral bioavailability
Evidence level	Extensive preclinical; Mayo Clinic-backed; Phase II trial active

Mechanism Summary

Senolytic: BH3-Mimetic Apoptosis

Fisetin binds Bcl-2/Bcl-xL hydrophobic grooves → displaces BAX/BAK → mitochondrial outer membrane permeabilization → cytochrome c release → caspase-9 activation → apoptosis.

Additional senolytic pathways:

Disrupts FOXO4-p53 complex → restores apoptotic p53 signaling
Inhibits PI3K/Akt/mTOR → removes survival signals keeping cells in senescent state
Destabilizes chaperone-dependent survival proteins via kinase modulation

Fisetin vs Quercetin (Why the C5-OH Absence Matters)

Feature	Quercetin	Fisetin
Structure	3,3’,4’,5,7-pentahydroxyflavone	3,3’,4’,7-tetrahydroxyflavone
C5-OH	Present — creates steric repulsion	Absent — docks deeper in Bcl-xL pocket
Senolytic potency	Moderate (needs dasatinib pairing)	High (standalone)
logP (BBB penetration)	~1.5	3.2 — readily crosses BBB

The absence of C5-OH is the structural key: fisetin docks without steric clash in the Bcl-xL/STK4 binding pocket where quercetin cannot fully fit. logP 3.2 means fisetin penetrates the blood-brain barrier effectively — quercetin does not.

Senolytic vs Senomorphic — Delivery-Dependent

Formulation	Outcome	Evidence
Free fisetin (standard oral)	Senolytic — kills senescent cells	Mayo Clinic mouse models, in vivo
Liposome-encapsulated (2025)	Senomorphic — suppresses SASP, zero apoptosis	WI-38 + A549 doxorubicin models

Liposomal delivery may prevent fisetin from reaching mitochondrial Bcl-xL while still inhibiting cytosolic NF-κB — shifts mechanism from senolytic to senomorphic.

Neuroprotection Mechanisms

Mechanism	Effect
BDNF ↑ + TrkB activation	Synaptic plasticity, memory restoration
Tau binding (K18 fragment)	Blocks fibrilization of R2/R3 β-strands; breaks mature filaments; spares tubulin-binding
SIRT1 → Nrf2 → GPX4	Ferroptosis inhibition (essential; SIRT1 knockout abolishes protection)
NF-κB suppression	Reduces neuroinflammation
PINK1/Parkin	Supports mitophagy

What the current evidence suggests

Mayo Clinic screening: Fisetin = most potent natural senolytic in 10-flavonoid panel; extends healthspan and lifespan in Ercc1-/Δ progeroid mice and late-life wild-type C57BL/6 mice
Human AFFIRM-LITE (NCT03675724): Frail elderly, 20 mg/kg × 2 days/month — Phase II active, enrollment 2025–2026
2024 epigenetic pilot (n=10 healthy adults ≥50): 500 mg/day × 1 month/month × 6 months — 4/10 decreased biological age; 1/10 no change; 5/10 increased epigenetic age — strong signal to avoid prophylactic use in healthy non-frail adults
NAFLLD (Iran 2025): 80 mg/kg/day × 8 wks — improved insulin resistance, ER stress resolution, autophagy induction (AMPK ↑, mTOR ↓)
Radioresistant liver cancer (SNU 2024): Fisetin + radiation — PERK-ATF4-CHOP axis pushes ER stress past adaptation threshold → apoptosis in resistant cells
Confidence level: High for preclinical senolytic mechanism; moderate for human dosing (epigenetic acceleration signal in healthy adults is a meaningful caution)

Risks and Uncertainty

Risk	Detail
Warfarin contraindication	Potent CYP2C9 → S-warfarin accumulation → hemorrhagic crisis — strictly excluded from all trials
CYP2C19 interactions	Clopidogrel, omeprazole, lansoprazole
CYP1A2 interactions	Caffeine, tizanidine
Healthy adult warning	5/10 showed increased epigenetic age in 2024 pilot — do not use prophylactically in non-frail healthy people
Bioavailability	44.1% oral; high inter-individual variation; nanoparticle/cyclodextrin formulations substantially improve
Senolytic vs senomorphic	Delivery method determines mechanism — formulation matters for whether intermittent or continuous dosing is appropriate
Confidence level	High preclinical; moderate human (dose, long-term safety, optimal protocol not fully established)

Drug Interaction Summary

CYP Enzyme	Fisetin Effect	Drugs at Risk
CYP2C9	Potent inhibition	Warfarin (S-warfarin) — hemorrhagic crisis
CYP2C19	Potent inhibition	Clopidogrel, omeprazole, lansoprazole
CYP1A2	Potent inhibition	Caffeine, tizanidine
CYP2D6	Moderate inhibition	Various psychiatric drugs
CYP3A4	Weak-moderate	Statins, many others

Best Stack Context

Partner	Rationale
Rapamycin	mTOR inhibition from both compounds → additive SASP suppression; rapamycin autophagy + fisetin completes the autophagic clearance pathway
NMN NAD+	Shared NAD+-supportive environment; senolytics clear CD38+ cells → NMN works better post-clearance
Urolithin A	Mitophagy (PINK1/Parkin from fisetin + urolithin A) + senolytic from fisetin — complementary debris clearance
PCC1	Both senolytics; PCC1 = trimer/MOMP (mitochondrial); Fisetin = BH3-mimetic; different structural classes with complementary mechanisms; D+Q+F combo shown to mitigate dasatinib-induced epigenetic acceleration
Retatrutide	Fisetin clears senescent cells from GLP-1-induced catabolism; Retatrutide prevents new ones

Dosing Summary

Protocol	Dose	Frequency	Purpose
Mayo senolytic burst	20 mg/kg × 2 consecutive days	Monthly	Senolytic (kill senescent cells)
Neuroprotection	500 mg/day	Continuous	Senomorphic / cognitive protection

Fisetin + Quercetin are synergistic, not redundant. Quercetin handles circulating cytokines and acute inflammation; fisetin executes deep senescent cell clearance.

Vitals Knowledge Vault

Explorer